Fu, Michael
Pivodic, Aldina
Käck, Oskar
Costa-Scharplatz, Madlaina
Dahlström, Ulf
Lund, Lars H.
Funding for this research was provided by:
Novartis Sweden AB.
University of Gothenburg
Article History
Received: 7 July 2022
Accepted: 22 September 2022
First Online: 29 November 2022
Declarations
:
: MF has received grants from Novartis and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Vifor-Fresenius. AP has nothing related or unrelated to the present work. OK and MC‐S are employees of Novartis. OK was the Novartis study lead, which included project management, facilitation, and support with heart failure-specific scientific contribution to the protocol as well as development of the statistical analysis plan and manuscript. MC-S. was the Novartis Real World Evidence (RWE) lead, contributing scientific expertise in RWE study design during protocol development as well as finalization of the statistical analysis plan and manuscript development. UD has received grants from AstraZeneca, Boston Scientific, Boehringer Ingelheim, Pfizer, Roche Diagnostics and Vifor Pharma, and personal fees from Amgen, AstraZeneca, Pfizer and Novartis. All unrelated to the present manuscript. LHL has received personal fees from Abbott, Bayer, Medscape, Merck, Myokardia, Pharmacosmos, and Sanofi; grants and personal fees from AstraZeneca, Boehringer Ingelheim, Mundipharma, Novartis, Relypsa, and Vifor-Fresenius; grants from Boston Scientific.
: This study was conducted in accordance with the Guidelines for Good Pharmacoepidemiology Practices, followed the ethical principles laid down in the Declaration of Helsinki, fulfilled the criteria of a European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) study, and was in accordance with the ENCePP Code of Conduct. The study had ethics approval (permission number: DNR 2020-03988) and no identifiable personal information of the participants in this retrospective observational study will be provided to any outside entity. All registers except SwedeHF are administrative and do not require patient consent. SwedeHF is a quality register and does not require consent, but patients are informed of entry into national quality registers and allowed to opt out. This publication was developed in line with STROBE guidelines, summarized in the Supporting Information, Table S5<i>.</i>